Intracoronary infusion of CD133+ endothelial progenitor cells improves heart function and quality of life in patients with chronic post-infarct heart insufficiency

Flores-Ramírez, Ramiro; Uribe-Longoria, Artemio; Rangel-Fuentes, María M.; Gutiérrez-Fajardo, Pedro; Salazar-Riojas, Rosario; Cervantes‐García, Daniel; Treviño-Ortiz, José H.; Benavides-Chereti, Genoveva J.; Espinosa-Oliveros, Luciana P.; Limón-Rodríguez, Ramón H.; Monreal-Puente, Rogelio; González-Treviño, Juan Luis; Rojas-Martı́nez, Augusto

doi:10.1016/j.carrev.2009.04.001

Cited by 39 publications

(22 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to Davy et al [16] enrichment of autologous bone marrow CD34 + stem cells could increase the efficacy of treatments in clinical settings. Despite the fact that CD34 + cells have been the selected option for heart repair, there are also some reports of CD133 + cells applied in clinical trials showing improvement of myocardial viability and local perfusion of the infarcted zone [17][18][19][20][21][22]. However, none of these studies have shown de novo formation of cardiac muscle.…”

Section: Introductionmentioning

confidence: 99%

Engraftment of pre-differentiated stem cells into cardiomyocytes in an animal model of ischemic cardiopathy

González‐Garza

Alcaraz²,

Gonzalez-Jara³

et al. 2014

SCD

View full text Add to dashboard Cite

Stem cell therapy for cardiac infarct regeneration has been widely used in clinical research. Despite the fact that important advances in this field have been reached, the observed recovery does not demonstrate new cardiac muscle formation. Benefits have been observed due to an improvement in neovascularisation. The main objective of this study was to determine if predifferentiated stem cells into cells of myocardic lineage are capable of engraftment in animal models with induced cardiac infarct and are capable of truly differentiating into myocardiocytes. Bone marrow rat stem cells were predifferentiated with 5-AZ. After 4 weeks, pre-differentiated stem cells express muscarinic 1, 2 and β adrenergic 2 receptors. Also, proteins such as sarcomeric α-actin, cardiac myosin heavy chain, desmin and vimentin were detected by immunocytochemistry. Cells were transplanted intracardialy in an ischemic cardiac rat model. Pre-differentiated or non differentiated cells were transplanted after 4 weeks post infarct induction. Histopathology of the hearts was made 2 weeks after cell transplantation. Typical granulated tissue, scare formation and neovascularisation were observed in both groups. However, in those hearts from rats inoculated with pre-differentiated cells many appeared atypical and were α-actin sarcomeric positive. These events suggest that pre-differentiated cells conserve some muscle characteristic traits in situ that at least last for two weeks after transplantation.

show abstract

Section: Introductionmentioning

confidence: 99%

Engraftment of pre-differentiated stem cells into cardiomyocytes in an animal model of ischemic cardiopathy

González‐Garza

Alcaraz²,

Gonzalez-Jara³

et al. 2014

SCD

View full text Add to dashboard Cite

show abstract

“…However, some studies have refuted that HSCs, represented by lin-negative, sca1-positive, and c-kit-positive, do not transdifferentiate into any cardiomyocytes, after transplantation, in a mouse MI model [48, 49]. While no other specific human HSCs have been used, human CD34 + [17, 27, 47, 90] and CD133 + cells [91-93] were used in experiments reporting that post-MI cardiac function has been improved, conversely, through non-cardiomyogenic effects. The need for the use of mobilizing cytokines, such as G-CSF, to collect sufficient amount of CD34+ or CD133+ cells expenses high cost for clinical application and may result in a risk to patients.…”

Section: Hematopoietic Stem Cells (Hscs)mentioning

confidence: 99%

Cardiovascular repair with bone marrow-derived cells

2013

View full text Add to dashboard Cite

While bone marrow (BM)-derived cells have been comprehensively studied for their propitious pre-clinical results, clinical trials have shown controversial outcomes. Unlike previously acknowledged, more recent studies have now confirmed that humoral and paracrine effects are the key mechanisms for tissue regeneration and functional recovery, instead of transdifferentiation of BM-derived cells into cardiovascular tissues. The progression of the understanding of BM-derived cells has further led to exploring efficient methods to isolate and obtain, without mobilization, sufficient number of cell populations that would eventually have a higher therapeutic potential. As such, hematopoietic CD31+ cells, prevalent in both bone marrow and peripheral blood, have been discovered, in recent studies, to have angiogenic and vasculogenic activities and to show strong potential for therapeutic neovascularization in ischemic tissues. This article will discuss recent advancement on BM-derived cell therapy and the implication of newly discovered CD31+ cells.

show abstract

“…These studies were performed in murine HSCs and no such experiments were conducted with specific human HSCs other than CD34 + cells and CD133 + cells that are enriched with human HSCs and EPCs. Studies using human CD34 + cells [47–50] or CD133 + cells [51–53] have been reported to improve post-MI cardiac function; however, the therapeutic mechanism turned out to be from nontransdifferentiation effects. As CD34 + cells or CD133 + cells are present in low numbers in circulation, the use of mobilizing cytokines such as granulocyte-colony stimulating factor (G-CSF) for obtaining a large number of cells needed for clinical use incurs high costs and risk to patients.…”

Section: Hematopoietic Stem Cellsmentioning

confidence: 99%

Advances in Bone Marrow-Derived Cell Therapy: CD31-expressing Cells as Next Generation Cardiovascular Cell Therapy

Kim

Yoon

2011

Regen. Med.

View full text Add to dashboard Cite

In the past few years, bone marrow (BM)-derived cells have been used to regenerate damaged cardiovascular tissues post-myocardial infarction. Recent clinical trials have shown controversial results in recovering damaged cardiac tissue. New progress has shown that the underlying mechanisms of cell-based therapy relies more heavily on humoral and paracrine effects rather than on new tissue generation. However, studies have also reported the potential of new endothelial cell generation from BM cells. Thus, efforts have been made to identify cells having higher humoral or therapeutic effects as well as their surface markers. Specifically, BM-derived CD31+ cells were isolated by a surface marker and demonstrated high angio-vasculogenic effects. This article will describe recent advances in the therapeutic use of BM-derived cells and the usefulness of CD31+ cells.

show abstract

Intracoronary infusion of CD133+ endothelial progenitor cells improves heart function and quality of life in patients with chronic post-infarct heart insufficiency

Cited by 39 publications

References 14 publications

Engraftment of pre-differentiated stem cells into cardiomyocytes in an animal model of ischemic cardiopathy

Engraftment of pre-differentiated stem cells into cardiomyocytes in an animal model of ischemic cardiopathy

Cardiovascular repair with bone marrow-derived cells

Advances in Bone Marrow-Derived Cell Therapy: CD31-expressing Cells as Next Generation Cardiovascular Cell Therapy

Contact Info

Product

Resources

About